92 related articles for article (PubMed ID: 38556549)
21. The methyl-CpG-binding domain 2 facilitates pulmonary fibrosis by orchestrating fibroblast to myofibroblast differentiation.
Wang Y; Zhang L; Huang T; Wu GR; Zhou Q; Wang FX; Chen LM; Sun F; Lv Y; Xiong F; Zhang S; Yu Q; Yang P; Gu W; Xu Y; Zhao J; Zhang H; Xiong W; Wang CY
Eur Respir J; 2022 Sep; 60(3):. PubMed ID: 35086828
[TBL] [Abstract][Full Text] [Related]
22. UALCAN: An update to the integrated cancer data analysis platform.
Chandrashekar DS; Karthikeyan SK; Korla PK; Patel H; Shovon AR; Athar M; Netto GJ; Qin ZS; Kumar S; Manne U; Creighton CJ; Varambally S
Neoplasia; 2022 Mar; 25():18-27. PubMed ID: 35078134
[TBL] [Abstract][Full Text] [Related]
23. Hallmarks of Cancer: New Dimensions.
Hanahan D
Cancer Discov; 2022 Jan; 12(1):31-46. PubMed ID: 35022204
[TBL] [Abstract][Full Text] [Related]
24. Navigating the DNA methylation landscape of cancer.
Nishiyama A; Nakanishi M
Trends Genet; 2021 Nov; 37(11):1012-1027. PubMed ID: 34120771
[TBL] [Abstract][Full Text] [Related]
25. Hypoxia-Induced Suppression of Alternative Splicing of MBD2 Promotes Breast Cancer Metastasis via Activation of FZD1.
Liu Z; Sun L; Cai Y; Shen S; Zhang T; Wang N; Wu G; Ma W; Li ST; Suo C; Hao Y; Jia WD; Semenza GL; Gao P; Zhang H
Cancer Res; 2021 Mar; 81(5):1265-1278. PubMed ID: 33402389
[TBL] [Abstract][Full Text] [Related]
26. Forkhead-box A3 (FOXA3) represses cancer stemness and partially potentiates chemosensitivity by targeting metastasis-associated in colon cancer 1 (MACC1) signaling pathway in colorectal cancer cells.
Li N; Li Y; Gao H; Li J; Ma X; Liu X; Gong P; Cui X; Li Y
Curr Cancer Drug Targets; 2020 Dec; ():. PubMed ID: 33292133
[TBL] [Abstract][Full Text] [Related]
27. MBD2 serves as a viable target against pulmonary fibrosis by inhibiting macrophage M2 program.
Wang Y; Zhang L; Wu GR; Zhou Q; Yue H; Rao LZ; Yuan T; Mo B; Wang FX; Chen LM; Sun F; Song J; Xiong F; Zhang S; Yu Q; Yang P; Xu Y; Zhao J; Zhang H; Xiong W; Wang CY
Sci Adv; 2021 Jan; 7(1):. PubMed ID: 33277324
[TBL] [Abstract][Full Text] [Related]
28. Active turnover of DNA methylation during cell fate decisions.
Parry A; Rulands S; Reik W
Nat Rev Genet; 2021 Jan; 22(1):59-66. PubMed ID: 33024290
[TBL] [Abstract][Full Text] [Related]
29. S-adenosylmethionine in combination with decitabine shows enhanced anti-cancer effects in repressing breast cancer growth and metastasis.
Mahmood N; Arakelian A; Cheishvili D; Szyf M; Rabbani SA
J Cell Mol Med; 2020 Sep; 24(18):10322-10337. PubMed ID: 32720467
[TBL] [Abstract][Full Text] [Related]
30. EO771, the first luminal B mammary cancer cell line from C57BL/6 mice.
Le Naour A; Koffi Y; Diab M; Le Guennec D; Rougé S; Aldekwer S; Goncalves-Mendes N; Talvas J; Farges MC; Caldefie-Chezet F; Vasson MP; Rossary A
Cancer Cell Int; 2020; 20():328. PubMed ID: 32699527
[TBL] [Abstract][Full Text] [Related]
31. uPAR antibody (huATN-658) and Zometa reduce breast cancer growth and skeletal lesions.
Mahmood N; Arakelian A; Khan HA; Tanvir I; Mazar AP; Rabbani SA
Bone Res; 2020; 8():18. PubMed ID: 32337090
[TBL] [Abstract][Full Text] [Related]
32. dbEMT 2.0: An updated database for epithelial-mesenchymal transition genes with experimentally verified information and precalculated regulation information for cancer metastasis.
Zhao M; Liu Y; Zheng C; Qu H
J Genet Genomics; 2019 Dec; 46(12):595-597. PubMed ID: 31941584
[No Abstract] [Full Text] [Related]
33. Rational discovery of antimetastatic agents targeting the intrinsically disordered region of MBD2.
Kim MY; Na I; Kim JS; Son SH; Choi S; Lee SE; Kim JH; Jang K; Alterovitz G; Chen Y; van der Vaart A; Won HS; Uversky VN; Kim CG
Sci Adv; 2019 Nov; 5(11):eaav9810. PubMed ID: 31799386
[TBL] [Abstract][Full Text] [Related]
34. OPN promotes the aggressiveness of non-small-cell lung cancer cells through the activation of the RON tyrosine kinase.
Hao C; Cui Y; Chang S; Huang J; Birkin E; Hu M; Zhi X; Li W; Zhang L; Cheng S; Jiang WG
Sci Rep; 2019 Dec; 9(1):18101. PubMed ID: 31792339
[TBL] [Abstract][Full Text] [Related]
35. The E-Cadherin and N-Cadherin Switch in Epithelial-to-Mesenchymal Transition: Signaling, Therapeutic Implications, and Challenges.
Loh CY; Chai JY; Tang TF; Wong WF; Sethi G; Shanmugam MK; Chong PP; Looi CY
Cells; 2019 Sep; 8(10):. PubMed ID: 31547193
[TBL] [Abstract][Full Text] [Related]
36. The diverse roles of DNA methylation in mammalian development and disease.
Greenberg MVC; Bourc'his D
Nat Rev Mol Cell Biol; 2019 Oct; 20(10):590-607. PubMed ID: 31399642
[TBL] [Abstract][Full Text] [Related]
37. SPARC Is a New Myeloid-Derived Suppressor Cell Marker Licensing Suppressive Activities.
Sangaletti S; Talarico G; Chiodoni C; Cappetti B; Botti L; Portararo P; Gulino A; Consonni FM; Sica A; Randon G; Di Nicola M; Tripodo C; Colombo MP
Front Immunol; 2019; 10():1369. PubMed ID: 31281314
[TBL] [Abstract][Full Text] [Related]
38. DNA Methylation Readers and Cancer: Mechanistic and Therapeutic Applications.
Mahmood N; Rabbani SA
Front Oncol; 2019; 9():489. PubMed ID: 31245293
[TBL] [Abstract][Full Text] [Related]
39. Metascape provides a biologist-oriented resource for the analysis of systems-level datasets.
Zhou Y; Zhou B; Pache L; Chang M; Khodabakhshi AH; Tanaseichuk O; Benner C; Chanda SK
Nat Commun; 2019 Apr; 10(1):1523. PubMed ID: 30944313
[TBL] [Abstract][Full Text] [Related]
40. SPARC promotes the proliferation and metastasis of oral squamous cell carcinoma by PI3K/AKT/PDGFB/PDGFRβ axis.
Jing Y; Jin Y; Wang Y; Chen S; Zhang X; Song Y; Wang Z; Pu Y; Ni Y; Hu Q
J Cell Physiol; 2019 Sep; 234(9):15581-15593. PubMed ID: 30706473
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
